Skip to content

Study on the clinical and immunological mechanism of Yu-fei-ning Prescription in the treatment of chronic obstructive pulmonary disease

Study on the clinical and immunological mechanism of Yu-fei-ning Prescription in the treatment of chronic obstructive pulmonary disease

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-17013577
Enrollment
Unknown
Registered
2017-11-28
Start date
2013-01-01
Completion date
Unknown
Last updated
2017-12-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD

Interventions

Yufeining group:decoction granules of Yufeining
placebo group:placebo

Sponsors

Zhangzhou Hospital of Traditional Chinese Medicine of Fujian Province
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. COPD group: (1) Aged 40-80 years old, male and femal; (2) confirmed diagnosis of COPD based on the diagnostic criteria, the COPD status had to be stable, with at grade III-IV; (3) In TCM syndrome differentiation criteria for lung, spleen and kidney deficiencies associated with retention of phlegm and blood stasis. 2. Healthy control group: (1) Aged 40-80 years old, male and female, physical examination was normal and no smoking history; (2) No acute or chronic respiratory diseases; (3) No cardiovascular diseases and diabetes mellitus; (4) No autoimmune diseases; (5) No allergic or hereditary allergic diseases; (6) Antibiotics and corticosteroids were not used in the past 1 month; (7) No obvious abnormality in chest X-ray examination; (8) Normal blood routine and blood ester and lung function.

Exclusion criteria

Exclusion criteria: 1. Patients were diagnosed with acute upper respiratory tract infections in the past two weeks; 2. Exacerbations in COPD; 3. Systemic corticosteroids were used in the past month; 4. Although the airflow obstruction, but clinical diagnosis of bronchial asthma, pulmonary tuberculosis, cystic fibrosis, diffuse bronchiolitis, bronchiolitis obliterans; 5. Patients were diagnosed with serious cardiovascular, liver, kidney or hematopoietic diseases; patients were diagnosed with psychiatric disorders; 6. Pregnant or lactating women; ?Unwilling to cooperate and completely unable to communicate.

Design outcomes

Primary

MeasureTime frame
COPD assessment test;mMRC;6-minute walking distance;Interleukin 8;Interleukin 17A;tumor necrosis factor a;transforming growth factor ß1;LTB4;

Countries

China

Contacts

Public ContactHong Minli

Zhangzhou Hospital of Traditional Chinese Medicine of Fujian Province

1501499678@qq.com+86 18960058823

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 23, 2026